+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Emergency Contraceptive Pills Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • PDF Icon

    Report

  • 177 Pages
  • May 2026
  • Region: Global
  • TechSci Research
  • ID: 5908240
Free Webex Call
10% Free customization

Online Stores is the fastest growing sector, North America is the largest market

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The global market for emergency contraceptive pills is projected to expand from USD 621.89 million in 2025 to USD 803.84 million by 2031, achieving a compound annual growth rate of 4.37%. These pills, which are hormonal formulations designed to prevent pregnancy by suppressing ovulation or fertilization after unprotected sex or contraceptive failure, are primarily driven by increasing public awareness of reproductive health and their gradual reclassification to over-the-counter status in many regions. International efforts to improve access to family planning services for underserved communities further support this growth, with the United Nations Population Fund reporting that global reproductive health programs prevented 18 million unintended pregnancies in 2024, emphasizing the vital role of accessible contraceptive options.

Market Drivers

Restrictive abortion regulations significantly drive market volatility and demand, especially in areas where reproductive rights legal frameworks are changing. When access to abortion services becomes limited or unclear, consumers increasingly turn to emergency contraception as a crucial safeguard, resulting in immediate, defensive purchasing and stockpiling as individuals strive to maintain reproductive autonomy amidst legislative threats. For example, Winx Health experienced a 966% surge in sales of their morning-after pill within 60 hours of political events suggesting tighter regulations, as reported by CBS News in November 2024.

These fluctuations highlight how the potential for reduced healthcare access directly stimulates higher demand for these essential pharmaceuticals. Moreover, increasing public awareness and acceptance of emergency contraception, effectively promoted by educational campaigns and efforts to reduce stigma, contribute to stable long-term market growth. As misconceptions about these products decrease, a broader population segment is incorporating them into their reproductive health management. KFF's January 2025 report on 'Emergency Contraception' notes that 33% of US women aged 15 to 49 have used emergency contraceptive pills, indicating normalized usage. This acceptance supports wider global health objectives; in 2024, Family Planning 2030 stated that modern contraception prevented about 143 million unintended pregnancies in lower-middle-income regions, underscoring the vital role of accessible family planning resources.

Market Challenges

The primary obstacle to the growth of the global emergency contraceptive pills market is the strict regulatory environment in some developing regions. In numerous places, these medications are still restricted to prescription-only status, rather than being available over-the-counter. This legal requirement creates a significant logistical barrier because emergency contraception is highly time-sensitive, needing to be taken within a narrow 72 to 120-hour window after unprotected intercourse for optimal effectiveness. When patients must navigate appointments and obtain authorization, these delays often reduce the medication's efficacy, leading to decreased consumer confidence and lost sales.

Furthermore, these regulatory difficulties are often worsened by strong cultural and religious opposition, complicating distribution and limiting market reach. In conservative areas, stigmas related to reproductive health can result in pharmacies refusing to dispense or local rules overriding national permissions, thus disrupting the supply chain to consumers. This restricted access directly hinders market performance by reducing the potential customer base. The International Planned Parenthood Federation reported in 2025 that restrictive policy changes and service point closures led to approximately 9 million people worldwide losing access to essential reproductive healthcare, significantly limiting manufacturers' commercial growth in these territories.

Market Trends

A key emerging trend to overcome logistical and social barriers to access involves the placement of self-service vending machines in institutional environments, especially universities. These automated dispensers ensure 24/7 access to emergency contraception, removing the need for potentially stigmatizing face-to-face interactions with pharmacists. This method directly addresses the medication's time-sensitive nature by making it available instantly within student residential and academic areas, avoiding delays from clinic hours or appointments.

As of February 2024, over 60 colleges nationwide host these vending machines, as reported by WYPR, demonstrating a growing institutional dedication to providing immediate, accessible reproductive healthcare. Concurrently, over-the-counter access is expanding beyond pharmacies into popular retail outlets like convenience stores to fill geographical availability gaps.

Manufacturers are focusing on "contraceptive deserts" - areas without pharmacies or clinics - by stocking generic levonorgestrel formulations in everyday stores with extended hours. This approach separates access from conventional pharmacy constraints and significantly eases the travel burden for consumers in rural or underserved areas who previously had limited supply options. Cadence OTC confirmed this strategic industry move in September 2024, identifying about 7,000 US zip codes as emergency contraceptive deserts, thereby validating the use of convenience stores to address significant supply chain gaps.

Key Market Players

  • Afaxys Pharma LLC
  • Bayer AG
  • Combe Inc.
  • Foundation Consumer Healthcare LLC
  • Gedeon Richter Plc
  • HLL Lifecare Ltd.
  • Knoll Healthcare Pvt. Ltd.
  • Laboratoire HRA Pharma SAS
  • Lupin Ltd.
  • Mankind Pharma Ltd.

Report Scope

In this report, the Global Emergency Contraceptive Pills Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Emergency Contraceptive Pills Market, by Type:

  • Combination Pills
  • Progesterone Pills
  • Others

Emergency Contraceptive Pills Market, by Distribution Channel:

  • Retail Stores
  • Online Stores
  • Others

Emergency Contraceptive Pills Market, by Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Emergency Contraceptive Pills Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Emergency Contraceptive Pills Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Combination Pills, Progesterone Pills, Others)
5.2.2. By Distribution Channel (Retail Stores, Online Stores, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Emergency Contraceptive Pills Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Emergency Contraceptive Pills Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Distribution Channel
6.3.2. Canada Emergency Contraceptive Pills Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Distribution Channel
6.3.3. Mexico Emergency Contraceptive Pills Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Distribution Channel
7. Europe Emergency Contraceptive Pills Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Emergency Contraceptive Pills Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Distribution Channel
7.3.2. France Emergency Contraceptive Pills Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Distribution Channel
7.3.3. United Kingdom Emergency Contraceptive Pills Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Emergency Contraceptive Pills Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Distribution Channel
7.3.5. Spain Emergency Contraceptive Pills Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Distribution Channel
8. Asia Pacific Emergency Contraceptive Pills Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Emergency Contraceptive Pills Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Distribution Channel
8.3.2. India Emergency Contraceptive Pills Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Distribution Channel
8.3.3. Japan Emergency Contraceptive Pills Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Distribution Channel
8.3.4. South Korea Emergency Contraceptive Pills Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Distribution Channel
8.3.5. Australia Emergency Contraceptive Pills Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Distribution Channel
9. Middle East & Africa Emergency Contraceptive Pills Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Emergency Contraceptive Pills Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Distribution Channel
9.3.2. UAE Emergency Contraceptive Pills Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Distribution Channel
9.3.3. South Africa Emergency Contraceptive Pills Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Distribution Channel
10. South America Emergency Contraceptive Pills Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Emergency Contraceptive Pills Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Distribution Channel
10.3.2. Colombia Emergency Contraceptive Pills Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Distribution Channel
10.3.3. Argentina Emergency Contraceptive Pills Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Emergency Contraceptive Pills Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Afaxys Pharma LLC
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Bayer AG
15.3. Combe Inc.
15.4. Foundation Consumer Healthcare LLC
15.5. Gedeon Richter Plc
15.6. HLL Lifecare Ltd.
15.7. Knoll Healthcare Pvt. Ltd.
15.8. Laboratoire HRA Pharma SAS
15.9. Lupin Ltd.
15.10. Mankind Pharma Ltd.
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

  • Afaxys Pharma LLC
  • Bayer AG
  • Combe Inc.
  • Foundation Consumer Healthcare LLC
  • Gedeon Richter Plc
  • HLL Lifecare Ltd.
  • Knoll Healthcare Pvt. Ltd.
  • Laboratoire HRA Pharma SAS
  • Lupin Ltd.
  • Mankind Pharma Ltd.

Table Information